Studieoverzicht
Study name: TNO155
Histology | NSCLC | ||
---|---|---|---|
Tumor stage | Stage III - IV | ||
Host / recruiting site 1 | Erasmus MC | Enrollment | On hold |
Therapy line | Later line (≥2L) | ||
Design |
Open-label, multi-center, fase I, dose finding studie met oraal TNO155 in volwassen patienten met gemetastaseerd NSCLC met KRAS G12C mutatie (expansie fase) |
||
Intervention |
|
||
Key outcome parameters |
|
||
Key inclusion criteria |
|
||
Key exclusion criteria |
|
||
Contact information | Log in voor de contactinformatie |